return equiti ttm
expect baxter updat investor analyst day next week thought longer-
term guidanc compani follow pattern past analyst day expect
outlook remain five year potenti new target compani may
also look updat previous publish target
look three area discuss
strateg plan believ continu move baxter mix toward high-
margin segment like acut therapi advanc surgeri pharmaceut
top-lin growth like acceler out-year five-
year plan bar potenti acquisit opinion though compani alreadi
made invest posit better growth
driver oper margin expans believ sg becom
smaller factor five-year period larger shift gross margin relat product
dive three interlac subject expect manag guidanc
meet beat investor long-term expect strateg move toward high-growth
high-margin segment drive oper margin near term sever
competit headwind top-lin oper margin growth though
reflect manag guidanc
stock trade time non-gaap ep estim
time non-gaap ep estim premium multipl
peer ev/ebitda basi stock trade time ebitda estim
billion time ebitda estim billion line
premium peer
believ baxter put right piec place strateg drive sustain
top-lin growth improv gross margin profil long-term basi though still
earli process realloc invest toward profit geographi
product categori believ chang take coupl year
becom materi rate stock market perform news flow
trajectori stori like construct aggress investor may want
take look stock
lead develop manufactur distributor wide varieti medic product
dialysi equip dispos servic intraven infus set solut
stock thought valuat
pleas refer import disclosur page analyst certif page
william blair affili seek busi compani cover research report
result investor awar firm may conflict interest could affect object
report report intend provid person invest advic opinion recommend
herein take account individu client circumst object need intend
recommend particular secur financi instrument strategi particular client recipi
report must make independ decis regard secur financi instrument mention
sg sinc spin bioscienc divis baxter exceed prior guidanc level alreadi revamp
cost structur expand oper margin drive improv
date sg expens percentag sale decreas nearli basi point period go
forward sg percentag sale continu area leverag believ unlik see
level reduct prior year alreadi peer believ reduc sg percentag sale
long-term roughli basi point current guidanc reason target compani
continu implement cost-cut initi move certain program high-cost locat lower-cost
locat view sg expens percentag sale less achiev
background may investor day baxter outlin initi lrp oper margin reach
compani nearli reach target first year thu increas expect
second quarter result current estim rapid oper margin expans
mainli factor strong sg leverag decreas sale sale
implement zero base budget
gross margin outsid sg leverag believ baxter continu expand oper margin via gross margin
improv compani made number move last sever year focus invest busi
segment higher top-lin growth margin corpor averag street gross margin estim
appear roughli versu compani end consist manag
see path acceler revenu growth improv gross margin profil base baxter strateg invest
thu make compani less reliant sg leverag sustain earn growth believ street
look valuat howev believ major gross margin upsid like begin manifest beyond
street current outlook near-term expans within next one two year prove difficult come
gross margin analysi suggest baxter product segment gross margin higher corpor averag includ
acut therapi total sale estim mid- gross margin like higher
corpor averag grow faster rate baxter overal busi expect grow constant
currenc versu constant currenc overal busi base focus invest baxter
make drive higher long-term monitor consum util believ above-averag growth
sustain categori drive posit mix shift lift overal gross margin time said busi
remain smaller piec baxter overal busi take time develop bar potenti
baxter william blair co inc oper margin contributorsdollar valuegrowthimpact opsg reduct largest impact op expansionin largest increas om revenu contribut op beat part driven acquisit william blair
total sale estim gross margin profil like largest
contributor gross margin expans time margin possibl though near term present
competit headwind still compani multipl product launch molecul gener inject
add increment gross margin improv start late
advanc surgeri total sale estim gross margin recent acquisit two
product baxter like abil leverag exist salesforc drive growth
manag expect addit roughli basi point report top-lin growth roughli posit
benefit ep longer term product line grow believ could larger benefit gross margin
medic deliveri total sale seen gross margin expans last year estim
segment gross margin current sit high expect gross margin stabl modestli lower
compani launch new pump near term second half expand time recur
higher margin dispos stream becom larger percentag sale
higher margin busi becom larger percentag sale posit contribut gross margin
improv would expect baxter continu make acquisit high margin segment like
advanc surgeri could acceler growth bolster gross margin quicker outlin specif driver
segment expect drive higher revenu growth longer term base anticip revenu
margin drag product launch timelin believ revenu growth margin improv like step
beyond versu materi chang
acut therapi near term broader launch compani prismax continu renal replac therapi
crrt monitor europ drive replac monitor capit sale accret top line though capit tend
lower margin sale product expect simplifi usabl icu could allow compani expand
filtrat outsid indic acut kidney injuri longer term set apart compet devic geograph
perspect penetr europ acut kidney injuri high could limit upsid amount addit
higher-margin consum revenu driven though expand indic approv oxiri blood
purif set could modest driver increas capit util
longer term prismax launch unit state expect capit sale accret top line quickli
consum sale like accret gross margin beyond believ domest penetr crrt
patient acut kidney injuri less suggest baxter opportun replac exist
prismaflex system open new account manag suggest compani also opportun drive higher
consum growth within exist account mani system util much could
pharmaceut expect categori gross margin expans potenti longer term new high
margin molecul higher margin gener inject launch next sever year still baxter need get past
near-term headwind see benefit manag guidanc call revenu growth
drag gross margin three main reason
million cyclophosphamid headwind expect revenu million versu million
roughli basi point top-lin headwind gross margin product
note baxter bake headwind cyclophosphamid year though move gener
competit taken longer expect consist sourc upsid estim
manag alreadi rais expect product though past increas
guidanc nearli everi quarter last sever year declin similar year
could see ep upsid full year
brevibloc competit first quarter competit suppli constraint caus sale come higher expect
guidanc conserv assum competit ramp back second quarter year said
competit delay could addit upsid
invest manufactur qualiti recent acquir clari revenu expect expand
million million adjust ebitda margin like come
histor rang interim come back
look forward baxter look launch multipl new molecul begin late benefit top-
bottom-lin growth date baxter launch new molecul premix expect come market six
anti-infect molecul three oncolyt molecul four molecul therapeut area four molecul
cumul repres roughli million peak sale largest individu molecul peak sale million
million suggest major potenti sale total product pipelin still come baxter estim
cumul peak sale molecul million addit manag believ one two
molecul still launch could higher largest molecul compani launch date expect
molecul could similar gross margin profil baxter pharmaceut buoy metric
longer term
look even necessari patent expir baxter begin launch five gener
anti-canc lung multipl myeloma breast anti-naus nausea vomit inject compound develop
scinopharm current cumul brand sale billion expect baxter use scale expertis
develop otherwis difficult manufactur compound attract gross margin like addit
five inject baxter right add inject product collabor scinopharm could
provid addit high margin revenu stream compani bake long-term estim expect manag
provid color upcom analyst day
advanc surgeri near term baxter recent acquisit recothrom preveleak hemostat
sealant use case intraop bleed may occur add increment roughli million baxter
top line advanc surgeri busi one better gross margin profil baxter assum two product
gross margin similar rest busi recothrom sale origin expect flatten declin
manag given baxter exist sale market infrastructur hospit relationship
expect baxter drive growth product along preveleak like littl addit oper cost
baxter also recent launch tisseel prima next-gener fibrin sealant europ product improv
surgeon speed precis control deliv believ increas spend core growth hemostat
sealant busi allow compani come regular cadenc new products/ind bolster
growth gross margin longer term
medic deliveri baxter launch sigma spectrum iq infus pump second half fda approv
came mid-may product nice step-up compani improv focus clinic outcom clinician
ease-of-us cost save new featur includ auto-program auto-document integr two-way
connect baxter done solid job regain infus pump share industri sinc colleagu recal though
one largest updat product sinc expect devic competit other market
though initi drive capit placement headwind gross margin dispos follow-through come time
still pump placement benefit gross margin dollar could fall benefit bottom line
near term higher margin dispos revenu begin benefit gross margin blend averag gross margin
pump dispos slightli higher corpor averag benefit compound
beyond compani also look launch new intern pump platform later year repres
new geograph opportun intern market especi europ syring market versu smart pump
may take time develop increment
renal believ renal gross margin periton dialysi pd center renal therapi servic rt
corpor averag gross margin expect compani focus in-cent becom less drag gross
margin near term compani exit certain lower revenu tender market launch new dialyz
initi bolster volum help modestli off-set price declin still put take
in-cent margin improv modestli increment pd growth materi driver margin
near term compani benefit new agreement outperform unit state
implement new telemonitor rule unit state may also benefit demand pd next-gener pd
product launch expect impact seen beyond baxter begun launch kaguya pd
technolog japan patient treat in-cent though need build market like take
time compani expect launch innov on-demand pd system though still sever year away
launch similarli take time gain materi traction
estim pd margin highest compon compani renal care margin rang versu mid-
in-cent pd growth acceler becom larger portion renal care busi would boost overal
gross margin higher given renal make largest portion baxter revenu potenti margin
improv could go long way though may take time develop
